Results 101 to 110 of about 504,655 (311)

RNA interference approaches for treatment of HIV-1 infection. [PDF]

, 2015
HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 replication and delay the onset of AIDS, viral mutagenesis often leads to
Bobbin, Maggie L, Burnett, John C, Rossi, John J   +2 more
core   +1 more source

The MMP‐9/TIMP‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS ...
Ivan Pavlovic, Ida Erngren, Kim Kultima, Anders Larsson, Malin Müller, Anna Wiberg, Joachim Burman   +6 more
wiley   +1 more source

Drug- Resistance- Associated Mutations and HIV Sub-Type Determination in Drug-Naïve and HIV-Positive Patients under Treatment with Antiretroviral Drugs

Medical Laboratory Journal, 2013
Background and Objective: Resistance to antiretroviral agents is a significant concern in clinical management of HIV-infected individuals. Resistance is the result of mutations that develops in the viral protein targeted by antiretroviral agents ...
H Naziri, A Tabarraei, A Ghaemi, MA Davarpanah, N Javid, A Moradi   +5 more
doaj  

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang, Lu Lu, Hui Gao, Qi Zhang, Jing Xiao, Josemir W. Sander, Weixi Xiong, Dong Zhou   +7 more
wiley   +1 more source

Prevention of viral drug resistance by novel combination therapy.

Current opinion in investigational drugs (London, England : 2000), 2001
A new form of antiviral clinical therapy is proposed in which three different drugs are administered against three different targets on the same virus-coded protein. If the physiological functions of the three different target sites are not independent of each other, then a mutation conferring drug resistance at one site may alter the physiological ...
Mangel, W. F., Brown, M. T., Baniecki, M. L., Barnard, Dale L., McGrath, W. J.   +4 more
openaire   +2 more sources

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, EarlyView.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source

WHAT CLINICIANS NEED TO KNOW ABOUT ANTIVIRAL DRUGS AND VIRAL RESISTANCE

Infectious Disease Clinics of North America, 1997
The development of safe and effective antiviral therapies for the management of a variety of viral infections has expanded tremendously in recent years. Treatment is now possible for serious and potentially life-threatening infections with herpesviruses, respiratory viruses such as influenza A and respiratory syncytial virus, and the human ...
openaire   +2 more sources

Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models

Advanced Functional Materials, EarlyView.
Structure–activity relationship (SAR) optimization of bio‐reducible ionizable lipids enables the development of highly effective lipid nanoparticle (LNP) mRNA vaccines. Lead LNPs show superior tolerability and antibody responses in rodents and primates, outperforming approved COVID‐19 vaccine lipids.
Ruben De Coen, Sabah Kasmi, Shrinivas Dumbre, Lies Baekens, Elise Seynaeve, Louise Van den Hauwe, Niccolò Cantini, Aello Garantoudi, Filipe Branco Madeira, Alain Marrot, Emma Tuypens, Sofie Seghers, Anna Kuchmiy, Elisabeth Brabants, Bart Vanderborght, Ine Maes, Sarah Vandenberghe, Jessica Filtjens, Alícia Gordún Peiró, Daliya Kancheva, Ayla Debraekeleer, Florence Lambolez, Emily De Lombaerde, Yong Chen, Rafael Miyazawa Martins, Pauline Formaglio, Damya Laoui, Sofie Deschoemaeker, Bruno G. De Geest, Rogerio Amino, Stefaan De Koker   +30 more
wiley   +1 more source

Transparent Inorganic–Organic Bilayer Neural Electrode Array and Integration to Miniscope System for In Vivo Calcium Imaging and Electrophysiology

Advanced Functional Materials, EarlyView.
This study presents the BioCLEAR system, a highly transparent and conductive neural electrode array composed of silver nanowires (AgNWs) and doped PEDOT:PSS, enabling neural recordings with minimal optical artifacts. When integrated with a GRIN lens, this cost‐effective neural implant allows simultaneous electrophysiological recording and GCaMP6‐based ...
Dongjun Han, Kevin Cheng, Swathy Sampath Kumar, Anil Bollimunta, Elizabeth E. Torr, Juhwan Kim, Kyoungmin Kim, Hyungjun Choi, Seongkwon Hwang, Sarah Brodnick, David Cheng, Lindsay Gray, Yei Hwan Jung, William L. Murphy, Aaron J. Suminski, Jonathan J. Nassi, Justin C. Williams, Dong‐Wook Park   +17 more
wiley   +1 more source

Establishment of drug-resistant HBV small-animal models by hydrodynamic injection

Acta Pharmaceutica Sinica B, 2014
In antiviral therapy of hepatitis B virus (HBV) infection, drug resistance remains a huge obstacle to the long-term effectiveness of nucleoside/tide analogs (NAs).
Junjun Cheng, Yanxing Han, Jian-Dong Jiang   +2 more
doaj   +1 more source